PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Bezlotoxumab→

Bezlotoxumab PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1246264-45-8
Molecular formula
Not available
Molecular weight
Not available
Drug class
Human monoclonal antibody against Clostridioides difficile toxin Brecurrence-prevention biologic
Mechanism of action
Binds and neutralises C. difficile toxin B, preventing toxin-mediated cellular injury. Bezlotoxumab does not treat the active infection directly and is administered as an adjunct to antibacterial treatment to reduce recurrence risk.
Indications / reported uses
  • Reduction of recurrence of Clostridioides difficile infection (CDI) in adults receiving antibacterial drug treatment for CDI who are at high risk of recurrence; not indicated as treatment for active CDI or as a substitute for antibacterial therapy

Sources: US DailyMed — ZINPLAVA (bezlotoxumab) prescribing information · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Bezlotoxumab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Bezlotoxumab Permitted Daily Exposure (PDE) report (the Bezlotoxumab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Bezlotoxumab Occupational Exposure Limit (OEL) report (the Bezlotoxumab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.